Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | TET3 | O43151 | 1/20 | 0.42 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.42 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18038731 | 0.87 | OPRL1 (0.59) | KMT2AALDH1A1LMNAMAPTOPRL1 | |
| SCHEMBL16423480 | 0.86 | KMT2A (0.51) | KMT2AALDH1A1MAPTOPRL1OPRM1 | |
| SCHEMBL6042399 | 0.84 | KMT2A (0.49) | KMT2AALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL654443 | 0.82 | KMT2A (0.47) | KMT2AALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL9876987 | 0.76 | OPRD1 (0.48) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL9876994 | 0.76 | OPRD1 (0.48) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL9876991 | 0.76 | OPRD1 (0.48) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL2229509 | 0.74 | MEN1 (0.62) | KMT2AALDH1A1OPRL1OPRM1MEN1 | |
| SCHEMBL27790061 | 0.74 | LMNA (0.44) | KMT2AALDH1A1LMNAMAPTOPRL1 | |
| SCHEMBL6042869 | 0.74 | ALDH1A1 (0.45) | KMT2AALDH1A1LMNAMAPTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102803258-B | Alkyl-heterocyclic carbamate derivatives, their preparation and therapeutic use | SAI NUOFEI (FR) | 2016-04-20 | — | — | CN | claimed |
| CN-102803258-A | Alkyl-heterocyclic carbamate derivatives, their preparation and therapeutic use | SANOFI AVENTIS | 2012-11-28 | — | — | CN | claimed |
| CN-105837565-A | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | 赛诺菲 | 2016-08-10 | — | — | CN | disclosed |
| CN-102803258-B | Alkyl-heterocyclic carbamate derivatives, their preparation and therapeutic use | SAI NUOFEI (FR) | 2016-04-20 | — | — | CN | disclosed |
| CN-102803258-B | Alkyl-heterocyclic carbamate derivatives, their preparation and therapeutic use | SAI NUOFEI (FR) | 2016-04-20 | — | — | CN | disclosed |
| EP-2173713-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-02-17 | — | — | EP | disclosed |
| US-8501782-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| CN-102803258-A | Alkyl-heterocyclic carbamate derivatives, their preparation and therapeutic use | SANOFI AVENTIS | 2012-11-28 | — | — | CN | disclosed |
| US-20100204274-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| EP-2173713-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009015164-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204274-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CXCR1, CCR1 | KMT2A 2401/4885ALDH1A1 972/4885LMNA 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.